Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge & 12 others Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, Lisa A. Gurski

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

Original languageEnglish (US)
Pages (from-to)1429-1440
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Thyroid Neoplasms
Guidelines
Carcinoma, Papillary, Follicular
Medullary Carcinoma
Carcinoma
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., ... Gurski, L. A. (2018). Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 16(12), 1429-1440. https://doi.org/10.6004/jnccn.2018.0089
Haddad, Robert I. ; Nasr, Christian ; Bischoff, Lindsay ; Busaidy, Naifa Lamki ; Byrd, David ; Callender, Glenda ; Dickson, Paxton ; Duh, Quan Yang ; Ehya, Hormoz ; Goldner, Whitney ; Haymart, Megan ; Hoh, Carl ; Hunt, Jason P. ; Iagaru, Andrei ; Kandeel, Fouad ; Kopp, Peter ; Lamonica, Dominick M. ; McIver, Bryan ; Raeburn, Christopher D. ; Ridge, John A. ; Ringel, Matthew D. ; Scheri, Randall P. ; Shah, Jatin P. ; Sippel, Rebecca ; Smallridge, Robert C. ; Sturgeon, Cord ; Wang, Thomas N. ; Wirth, Lori J. ; Wong, Richard J. ; Johnson-Chilla, Alyse ; Hoffmann, Karin G. ; Gurski, Lisa A. / Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2018 ; Vol. 16, No. 12. pp. 1429-1440.
@article{6274efbaac614ff3a47ef545d205115e,
title = "Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, H{\"u}rthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.",
author = "Haddad, {Robert I.} and Christian Nasr and Lindsay Bischoff and Busaidy, {Naifa Lamki} and David Byrd and Glenda Callender and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Whitney Goldner and Megan Haymart and Carl Hoh and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Peter Kopp and Lamonica, {Dominick M.} and Bryan McIver and Raeburn, {Christopher D.} and Ridge, {John A.} and Ringel, {Matthew D.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Rebecca Sippel and Smallridge, {Robert C.} and Cord Sturgeon and Wang, {Thomas N.} and Wirth, {Lori J.} and Wong, {Richard J.} and Alyse Johnson-Chilla and Hoffmann, {Karin G.} and Gurski, {Lisa A.}",
year = "2018",
month = "12",
day = "1",
doi = "10.6004/jnccn.2018.0089",
language = "English (US)",
volume = "16",
pages = "1429--1440",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "12",

}

Haddad, RI, Nasr, C, Bischoff, L, Busaidy, NL, Byrd, D, Callender, G, Dickson, P, Duh, QY, Ehya, H, Goldner, W, Haymart, M, Hoh, C, Hunt, JP, Iagaru, A, Kandeel, F, Kopp, P, Lamonica, DM, McIver, B, Raeburn, CD, Ridge, JA, Ringel, MD, Scheri, RP, Shah, JP, Sippel, R, Smallridge, RC, Sturgeon, C, Wang, TN, Wirth, LJ, Wong, RJ, Johnson-Chilla, A, Hoffmann, KG & Gurski, LA 2018, 'Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 12, pp. 1429-1440. https://doi.org/10.6004/jnccn.2018.0089

Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines. / Haddad, Robert I.; Nasr, Christian; Bischoff, Lindsay; Busaidy, Naifa Lamki; Byrd, David; Callender, Glenda; Dickson, Paxton; Duh, Quan Yang; Ehya, Hormoz; Goldner, Whitney; Haymart, Megan; Hoh, Carl; Hunt, Jason P.; Iagaru, Andrei; Kandeel, Fouad; Kopp, Peter; Lamonica, Dominick M.; McIver, Bryan; Raeburn, Christopher D.; Ridge, John A.; Ringel, Matthew D.; Scheri, Randall P.; Shah, Jatin P.; Sippel, Rebecca; Smallridge, Robert C.; Sturgeon, Cord; Wang, Thomas N.; Wirth, Lori J.; Wong, Richard J.; Johnson-Chilla, Alyse; Hoffmann, Karin G.; Gurski, Lisa A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 12, 01.12.2018, p. 1429-1440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

AU - Haddad, Robert I.

AU - Nasr, Christian

AU - Bischoff, Lindsay

AU - Busaidy, Naifa Lamki

AU - Byrd, David

AU - Callender, Glenda

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Goldner, Whitney

AU - Haymart, Megan

AU - Hoh, Carl

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Kopp, Peter

AU - Lamonica, Dominick M.

AU - McIver, Bryan

AU - Raeburn, Christopher D.

AU - Ridge, John A.

AU - Ringel, Matthew D.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Sippel, Rebecca

AU - Smallridge, Robert C.

AU - Sturgeon, Cord

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Wong, Richard J.

AU - Johnson-Chilla, Alyse

AU - Hoffmann, Karin G.

AU - Gurski, Lisa A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

AB - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85058746008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058746008&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0089

DO - 10.6004/jnccn.2018.0089

M3 - Article

VL - 16

SP - 1429

EP - 1440

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 12

ER -